Cassava Sciences Inc vs BlackRock TCP Capital Corp — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while BlackRock TCP Capital Corp trades at $3.9 (market cap $327.64M). The key difference: BlackRock TCP Capital Corp is far larger — about 6.9× Cassava Sciences Inc's market cap, and BlackRock TCP Capital Corp pays a 19.46% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | TCPC | |
|---|---|---|
Market Cap | $47.75M | $327.64M |
Sector | Health | Financials |
52-Week High | $4.64 | $7.26 |
52-Week Low | $0.87 | $3.13 |
Enterprise Value | -$34.93M | — |
Dividend Yield | — | 19.46% |
Signals from Pluang's Aura AI — not financial advice
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
TCPC trades at $4.00, up 1.52% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations at $0.22 per share, and the company completed a $523 million portfolio sale to reduce leverage. However, fundamentals show negative revenue and net income trends, with a low P/B of 0.59 suggesting potential undervaluation amid financial challenges.
The outlook is mixed: strategic actions and dividend yield near 8.5% offer value, but persistent losses, class action lawsuits, and high P/S ratio pose significant risks. Analyst consensus is cautious with more holds than buys, reflecting uncertainty over the company's turnaround efforts and profitability path.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →